A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration - Trial NCT01379560
Access comprehensive clinical trial information for NCT01379560 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sucampo Pharma Americas, LLC and is currently Completed. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 33 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sucampo Pharma Americas, LLC
Mallinckrodt
Timeline & Enrollment
Phase 2
May 01, 2011
Dec 01, 2011
Primary Outcome
Change in choroidal blood flow
Summary
The purpose of this study is to determine the pharmacodynamics of ocular blood flow
 measurements with multiple drop unoprostone isopropyl administration versus placebo in
 subjects with dry age-related macular degeneration (AMD).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01379560
Non-Device Trial